The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97)
For the relief of moderate to severe pain.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.